title: [The clinical study of invasive fungal infection in 76 cases of hematologic diseases].
abstract: OBJECTIVE
  To investigate the risk factors, clinical features, efficacy and adverse reactions in patients of hematologic diseases with invasive fungal infections (IFI).
  
  
  METHODS
  The risk factors and clinical features were retrospectively analyzed to compare the efficacy and safety of itraconazole with amphotericin B in treatment of IFI in 76 patients with hematologic diseases.
  
  
  RESULTS
  Of the 76 patients, 68 (89.5%) used broad-spectrum antibiotics, 64 (84.2%) were treated with more than 2 courses chemotherapy, 43 (56.6%) were under agranulocytosis, 34 (44.7%) were using glucocorticoid for long terms, 27 (35.5%) were with peripheral or central venous catheter. The overall effective rates of itraconazole and amphotericin B were 60.5% and 61.5% respectively (P = 0.929). There was a significant difference between itraconazole and amphotericin B in hypokalemia (14.0% vs 42.4%, P = 0.005) while no other differences in adverse reactions were found.
  
  
  CONCLUSIONS
  The risk factors of patients in hematologic diseases with IFI include chemotherapy, using broad septum antibiotics and agranulocysis. The therapeutic effect of itraconazole and amphotericin B in treatment of IFI is similar. The adverse reactions of itraconazole is less and slighter than amphotericin B.
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Fei-fei
authors.initials: FF
authors.lastname: Wu
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Si-lin
authors.initials: SL
authors.lastname: Gan
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.forename: Yan-fang
authors.initials: YF
authors.lastname: Liu
authors.forename: Xin-sheng
authors.initials: XS
authors.lastname: Xie
authors.forename: Ling
authors.initials: L
authors.lastname: Sun
authors.forename: Lin-xiang
authors.initials: LX
authors.lastname: Liu
authors.forename: Ding-ming
authors.initials: DM
authors.lastname: Wan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006402:Hematologic Diseases / Q000150:complications* / Q000382:microbiology; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B